Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack | Zendy

Pierre Amarenco | Zendy; Larry B. Goldstein | Zendy; Michael Szarek | Zendy; Henrik Sillesen | Zendy; Amy E. Rudolph | Zendy; Alfred Callahan | Zendy; Michael G. Hennerici | Zendy; Lisa Simunovic | Zendy; Justin A. Zivin | Zendy; K.M.A. Welch | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack

Author(s) -

Pierre Amarenco,

Larry B. Goldstein,

Michael Szarek,

Henrik Sillesen,

Amy E. Rudolph,

Alfred Callahan,

Michael G. Hennerici,

Lisa Simunovic,

Justin A. Zivin,

K.M.A. Welch

Publication year - 2007

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.107.493106

Subject(s) - medicine , stroke (engine) , atorvastatin , post hoc analysis , hazard ratio , placebo , cholesterol , cardiology , ischemic stroke , ischemia , confidence interval , mechanical engineering , alternative medicine , pathology , engineering

The intention-to-treat analysis of data from the placebo-controlled Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial found 80 mg atorvastatin per day reduced the risk of stroke and major coronary events in patients with recent stroke or transient ischemic attack. This benefit was present despite only a 78% net difference in adherence to randomized treatment over the course of the trial. In this exploratory analysis, our aim was to evaluate the benefit and risks associated with achieving a >or=50% low-density lipoprotein cholesterol (LDL-C) reduction from baseline.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research